bone

AlloSource Releases AlloFuse Line Extentsion

Company adds AlloFuse Select CM, a cellular allograft matrix, to the AlloFuse portfolio Centennial, Colo. — August 1, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue, and cellular allografts to advance patient healing in surgical procedures and wound care, today announced the release of AlloFuse® Select CM, a premium addition to AlloSource’s AlloFuse portfolio. AlloFuse Select CM combines osteoconductive, osteoinductive, and osteogenic properties to initiate and nurture bone growth, delivering the benefits of autograft bone without the potential drawbacks. The product is clinically proven to activate and support bone formation and can be used…